Insider buying last 90 days
No open-market insider purchases were filed for LIVN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LIVN insider filing, plotted on the chart in Gekko.Open LIVN in Gekko
NASDAQ: LIVN
LivaNova (LIVN) Stock Analysis & Forecast
Sep 28 close
$77.21+0.58 (+0.8%)
Gekko Brief
AI summaryCoverage of LivaNova this week centers on analyst sentiment and technical commentary rather than new operational news. One analysis frames LIVN as a healthcare innovator in Cardiopulmonary and Neuromodulation, citing a market cap of $4.31 billion, 10.80% revenue growth, and an average analyst target of $89.10 implying 13.98% upside. A separate piece examines the stock's price action through AI-generated trading strategies, describing a mid-channel oscillation pattern and divergent sentiment across timeframes.
LIVN closed at $77.21, up 0.8%, sitting between its 50-day average of $79.47 and 200-day average of $71.10. The stock is down 3.5% over the past month and 7% over three months, but up 24.8% over six months and 47.7% over the past year, within a 52-week range of $48.82 to $85.76. The GekkoIndex reads 61.8, placing LIVN in the Accumulation zone, with price 7.4% below the $83.36 Gekko Fair Value estimate.
The next earnings report is due 4 November 2026 before the open, 36 days out and beyond a typical 20-day hold; the prior quarter posted EPS of $0.86 versus an $0.80 estimate, a 2.8% reaction, continuing eight consecutive beats. Five analysts carry four buy ratings and one hold, with a consensus target of $89.10 implying 15.4% upside. Seasonally, the next 20 trading days have averaged -1.8% over five years, rising in only 2 of them.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
LivaNova price vs fair value
Close $77.21200-day averageGekko Fair Value $83.36
LivaNova quick facts
- Market cap
- $4.24B
- P/E ratio
- 22.8
- Forward P/E
- 16
- EPS, TTM
- $3.31
- Revenue, TTM
- $1.47B
- Profit margin
- 12.8%
- Dividend yield
- —
- Beta
- 0.87
- Volume
- 570,678 avg 650,869
- 1-year return
- +47.7%
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±6.2%
- 50-day average
- $79.47
- 200-day average
- $71.10
- Next earnings
- Nov 4 before open
- Shares outstanding
- 54.93M
LivaNova swing-trade checklist
LivaNova scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $77.21 sits between the 50-day ($79.47) and 200-day ($71.10) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
61.8, Accumulation
Reading 61.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
7.4% below
Price is 7.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−1.8% on average
From this point in the calendar, the next 20 trading days averaged −1.8% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
LivaNova stock chart and price history
LivaNova closed at $77.21 on Sep 28, 2026, +47.7% over the past year, inside a 52-week range of $48.82 to $85.76.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −3.5%
- 3 months
- −7.0%
- 6 months
- +24.8%
- 1 year
- +47.7%
The full LIVN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LIVN in Gekko
Follow LivaNova through every session
Put LIVN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LIVN in GekkoFree for 7 days. No credit card required.
About LivaNova
LivaNova develops and manufactures medical devices used in heart, lung, and nerve-related treatments. It is best known for its VNS Therapy System, an implanted device that stimulates the vagus nerve to help patients with drug-resistant epilepsy, hard-to-treat depression, and obstructive sleep apnea. The company also makes equipment used during heart-lung procedures, including oxygenators, heart-lung machines, and perfusion systems, along with temporary life support tools for cardiopulmonary and respiratory care.
The business is organized into three areas: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. Within Neuromodulation, LivaNova is also developing the VITARIA System, which applies vagus nerve stimulation to heart failure and remains in clinical development. Its customers include perfusionists, neurologists, neurosurgeons, and other physicians, along with hospitals and healthcare providers, reached through its own sales force and independent distributors. It also works with Verily on research into clinical biomarkers for depression.
LivaNova was founded in 1987 and is headquartered in London, United Kingdom. Its shares are listed on the NASDAQ under the ticker LIVN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- livanova.com
LivaNova GekkoIndex: the smart money zone
LivaNova’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.8, in the Accumulation zone, up 0.5 points over five sessions.
61.8Accumulation
Up 0.5 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 49 | +0.6% | +3.1% | ||
| Accumulation (current zone) | 195 | +1.7% | +5.2% | ||
| Neutral | 386 | 0.0% | +0.5% | ||
| Distribution | 40 | −1.0% | −1.3% | ||
| Selling | 2 | Too few readings yet | |||
Average LIVN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the LIVN price, zone by zone.Track LIVN in Gekko
Is LivaNova stock overvalued? Gekko Fair Value
LivaNova trades 7.4% below Gekko Fair Value of $83.36, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what LivaNova shares are worth, recalculated every trading day.
$83.36
Gekko Fair Value, Sep 26, 2026
7.4% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open LIVN in Gekko
LivaNova insider and Congress trading
No open-market insider purchases were filed for LivaNova, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in LIVN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for LIVN, plotted on the chart in Gekko.Open LIVN in Gekko
Buybacks
LivaNova has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2025
- $805K
- As a share of market cap
- 0.02%
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold LIVN.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
LivaNova earnings: next date and track record
LivaNova reports on Nov 4, 2026, before the open (36 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 36 days away
- EPS estimate
- $1.03
- Revenue estimate
- $381.1M
8 of 8reports beat the EPS estimate
±4.6%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 25, 2026 AI summary
- What they said
- LivaNova delivered strong 2025 performance with double-digit revenue growth, marking the fifth consecutive year of double-digit EPS growth and third consecutive year of double-digit organic revenue growth. Cardiopulmonary segment achieved $785 million revenue with 13% growth, driven by mid-teens HLM growth and Essence machine placements representing 55% of annual units. The company continues strategic focus on obstructive sleep apnea as a high-growth expansion opportunity while maintaining core business strength.
- Guidance
- Management provided top-line guidance for 2026, with some planned Essence placements and tender activity shifted from Q4 2025 into 2026. Strong demand for consumables continues with supply constraints in oxygenators market.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 25, 2026 | $0.86 est $0.80 | $360.9M est $353.3M | +2.8% |
| Nov 5, 2025 | $1.11 est $0.92 | $357.8M est $342.7M | −8.1% |
| Jul 29, 2025 | $1.05 est $0.87 | $352.5M est $342.1M | +1.3% |
| Apr 29, 2025 | $0.88 est $0.49 | $316.9M est $330.9M | −1.4% |
| Feb 19, 2025 | $0.81 est $0.80 | — | +1.7% |
| Oct 30, 2024 | $0.90 est $0.72 | $318.1M est $323.6M | −2.5% |
| Jul 31, 2024 | $0.93 est $0.78 | $318.6M est $304.2M | −5.8% |
| May 1, 2024 | $0.73 est $0.49 | $294.9M est $304.2M | +12.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
LivaNova stock forecast and analyst price targets
Analysts’ average 12-month price target for LivaNova is $89.10, +15.4% from the last close, from 5 firms rating the stock in the last 90 days.
$89.10consensus 12-month target, +15.4% from the last close
Now $77.21Avg $89.10
Low $81High $93
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 2 | Piper Sandler | $90 | +16.6% |
| Aug 21 | Mizuho Securities | — | — |
| Aug 5 | Stifel Nicolaus | $85 | +10.1% |
| Aug 5 | Needham | $93 | +20.5% |
| Jul 15 | Mizuho Securities | $95 | +23.0% |
+5.2%average 20-day move after past Accumulation readings
−1.8%average move over the next 20 trading days in the last 5 years
±2.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
LivaNova seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, LivaNova averaged −1.8% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.1% | 5 of 5 |
| Next 10 trading days | −3.0% | 2 of 5 |
| Next 15 trading days | −1.0% | 3 of 5 |
| Next 20 trading days | −1.8% | 2 of 5 |
| Next 30 trading days | +0.2% | 2 of 5 |
For scale, LIVN’s typical 20-trading-day move in either direction is about 6.2%.
LivaNova market cap and key statistics
LivaNova’s market cap is $4.24B, with a P/E ratio of 22.8 and revenue of $1.47B over the last twelve months.
Valuation
- Market cap
- $4.24B
- P/E ratio
- 22.8
- Forward P/E
- 16
- EPS, TTM
- $3.31
- Gekko Fair Value
- $83.36
Trading
- Volume
- 570,678
- Avg volume, 20 days
- 650,869
- 52-week high
- $85.76
- 52-week low
- $48.82
- Shares outstanding
- 54.93M
Financials
- Revenue, TTM
- $1.47B
- Profit margin
- 12.8%
- Return on equity
- 15.4%
- Quarterly earnings growth, YoY
- +287.8%
Risk and income
- Beta
- 0.87
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±6.2%
LivaNova stock news this week
Coverage of LivaNova this week reads neutral: 1 positive, 1 neutral and 1 negative headlines.
- LivaNova stock stays at USD 3.50 as 52-week range widensAD HOC NEWS, Sep 22
- LivaNova PLC (LIVN) Stock Analysis: A Healthcare Innovator with a 13.98% Upside PotentialDirectorsTalk Interviews, Sep 22
- (LIVN) Volatility Zones as Tactical TriggersStock Traders Daily, Sep 22
LivaNova peers
LivaNova’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
LivaNova stock FAQ
What is LivaNova’s market cap?
LivaNova’s market cap is $4.24B at the Sep 28, 2026 close of $77.21, with 54.93M shares outstanding. The shares trade on a P/E ratio of 22.8.
What is the LivaNova stock forecast?
The consensus analyst 12-month price target for LivaNova is $89.10, +15.4% from the last close. Of the 5 firms that rated the stock in the last 90 days, 4 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is LivaNova stock overvalued or undervalued?
On Gekko’s estimate LivaNova is undervalued: the Sep 28, 2026 close of $77.21 is 7.4% below Gekko Fair Value of $83.36. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does LivaNova report earnings next?
LivaNova is expected to report on Nov 4, 2026, before the market opens (36 days away). Analysts expect earnings of $1.03 per share on revenue of $381.1M. LivaNova beat the earnings estimate in 8 of its last 8 reports, moving 4.6% on average across the report.
What is LivaNova’s 52-week high and low?
LivaNova’s 52-week high is $85.76 and its 52-week low is $48.82; it closed at $77.21 on Sep 28, 2026, +47.7% over the past year. Over the last five years the shares peaked at $93.89 on Nov 5, 2021.
Is LivaNova stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See LivaNova the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.